In vitro bactericidal activity of iclaprim in human plasma.
This study evaluated the effect of human plasma on the in vitro bactericidal activity of the novel diaminopyrimidine iclaprim against methicillin (meticillin)-susceptible and -resistant Staphylococcus aureus strains. MICs and minimal bactericidal concentrations (MBCs) of iclaprim, with approximately 93% protein binding, were similar in the absence and in the presence of 50% human plasma; MICs and MBCs ranged from 0.06 to 0.125 microg/ml. Furthermore, the activity of iclaprim was not affected by plasma, with > or = 99.9% reduction in CFU after 5.0 to 7.6 h.
Laue
Heike
H
Arpida AG, Reinach, Switzerland. heike.laue@arpida.com
Valensise
Tiziana
T
Seguin
Aurélie
A
Lociuro
Sergio
S
Islam
Khalid
K
Hawser
Stephen
S
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D010949:Plasma; D011743:Pyrimidines / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D011743:Pyrimidines; C486448:iclaprim